BioSpace News Archive

Riverchase Dermatology and Cosmetic Surgery is honored to be named Cape Coral’s Best in Dermatology for 2019 by the News Press.

The Honourable Marie-Claude Bibeau, Minister of Agriculture and Agri-Food, and Under Secretary of Agriculture Greg Ibach, on behalf of Secretary of Agriculture Sonny Perdue, open the African Swine Fever Forum

Audentes Therapeutics, Inc. announced it has granted equity awards on April 24, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to nine individuals hired by Audentes from April 2 through April 24, 2019.

SparingVision, a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa (RP), announced that four communications (3 posters and 1 oral presentation) related to the SPVN06 gene therapy developed by SparingVision, will be presented during the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Charles Bier, MD with Charles J. Bier, M.D., PLLC / Washington Preventive Medicine & Longevity Center is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).

Data from three studies demonstrating new diagnostic and therapeutic utility of ThyroSeq® Genomic Classifier, offered commercially by CBLPath, a Sonic Healthcare Company, are being presented at the 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in Los Angeles, California.

Pennsylvania American Water is joining forces with the U.S. Drug Enforcement Agency to encourage participation in National Prescription Drug Take Back Day on April 27.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Libtayo® (cemiplimab).

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks.

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on non-small cell lung cancer on Thursday, May 2, from 5 to 9 p.m. at the Wyndham Pittsburgh University Center in Pittsburgh, Pennsylvania.